219 related articles for article (PubMed ID: 24327292)
1. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Bilusic M; Heery CR; Arlen PM; Rauckhorst M; Apelian D; Tsang KY; Tucker JA; Jochems C; Schlom J; Gulley JL; Madan RA
Cancer Immunol Immunother; 2014 Mar; 63(3):225-34. PubMed ID: 24327292
[TBL] [Abstract][Full Text] [Related]
2. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
Hörig H; Lee DS; Conkright W; Divito J; Hasson H; LaMare M; Rivera A; Park D; Tine J; Guito K; Tsang KW; Schlom J; Kaufman HL
Cancer Immunol Immunother; 2000 Nov; 49(9):504-14. PubMed ID: 11092617
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
Bernstein MB; Chakraborty M; Wansley EK; Guo Z; Franzusoff A; Mostböck S; Sabzevari H; Schlom J; Hodge JW
Vaccine; 2008 Jan; 26(4):509-21. PubMed ID: 18155327
[TBL] [Abstract][Full Text] [Related]
5. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
Ahn E; Kim H; Han KT; Sin JI
Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
Wansley EK; Chakraborty M; Hance KW; Bernstein MB; Boehm AL; Guo Z; Quick D; Franzusoff A; Greiner JW; Schlom J; Hodge JW
Clin Cancer Res; 2008 Jul; 14(13):4316-25. PubMed ID: 18594015
[TBL] [Abstract][Full Text] [Related]
7. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
8. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
10. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
[TBL] [Abstract][Full Text] [Related]
12. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
13. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Heery CR; Singh BH; Rauckhorst M; Marté JL; Donahue RN; Grenga I; Rodell TC; Dahut W; Arlen PM; Madan RA; Schlom J; Gulley JL
Cancer Immunol Res; 2015 Nov; 3(11):1248-56. PubMed ID: 26130065
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
17. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
[TBL] [Abstract][Full Text] [Related]
18. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
Marshall JL; Hawkins MJ; Tsang KY; Richmond E; Pedicano JE; Zhu MZ; Schlom J
J Clin Oncol; 1999 Jan; 17(1):332-7. PubMed ID: 10458251
[TBL] [Abstract][Full Text] [Related]
19. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
Xiang R; Primus FJ; Ruehlmann JM; Niethammer AG; Silletti S; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
J Immunol; 2001 Oct; 167(8):4560-5. PubMed ID: 11591784
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
